Published in Int J Radiat Oncol Biol Phys on September 19, 2008
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17
Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol (2013) 1.25
Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer (2009) 1.14
Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg (2012) 0.98
Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol (2012) 0.96
Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol (2011) 0.92
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol (2010) 0.89
Update on the management of cholangiocarcinoma. Dig Dis (2014) 0.87
A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol (2014) 0.87
Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol (2013) 0.86
Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol (2013) 0.84
Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford) (2013) 0.83
Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer (2015) 0.82
Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg (2014) 0.76
Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy-Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci (2015) 0.76
Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence. Radiat Oncol J (2016) 0.75
Cholangiocarcinoma--what level of evidence should we have? Int J Radiat Oncol Biol Phys (2009) 0.75
Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg (2013) 0.75
Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75
Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey. Radiat Oncol (2013) 0.75
Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma. J Gastrointest Oncol (2015) 0.75
Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol (2017) 0.75
The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea. Radiat Oncol J (2017) 0.75
External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol (2017) 0.75
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet (1969) 2.94
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
A review and update on cholangiocarcinoma. Oncology (2004) 2.49
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol (2005) 1.49
Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg (1997) 1.44
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys (2002) 1.31
The role of radiation therapy in cancer of the extra-hepatic biliary system: an analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys (1978) 1.25
Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2. Oncology (Williston Park) (2004) 1.19
Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol (2000) 1.15
Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology (2004) 1.10
Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys (1981) 1.10
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg (2004) 1.08
CT analysis of postoperative tumor recurrence patterns in periampullary cancer. Abdom Imaging (2003) 1.01
Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) (2002) 0.96
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology (2005) 3.01
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg (2003) 2.73
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys (2011) 2.54
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg (2004) 2.41
Clinical practice. Suspected appendicitis. N Engl J Med (2003) 2.38
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol (2011) 2.38
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys (2012) 2.12
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Intensity-modulated radiation therapy for anal cancer. Oncology (Williston Park) (2009) 2.07
A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. Oncology (Williston Park) (2011) 2.04
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. N Engl J Med (2004) 2.01
Does resident post graduate year influence the outcomes of inguinal hernia repair? Ann Surg (2005) 2.01
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
A genetic screen identifies novel non-compatible loxP sites. Nucleic Acids Res (2002) 1.99
Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96
Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med (2010) 1.89
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg (2011) 1.82
Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle (2008) 1.76
Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J (2006) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol (2006) 1.70
Failure-to-pursue rescue: explaining excess mortality in elderly emergency general surgical patients with preexisting "do-not-resuscitate" orders. Ann Surg (2012) 1.67
The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol (2009) 1.65
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys (2005) 1.64
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol (2004) 1.61
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg (2013) 1.58
Locally advanced pancreatic cancer. J Clin Oncol (2005) 1.55
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Resident education in the era of patient safety: a nationwide analysis of outcomes and complications in resident-assisted oncologic surgery. Ann Surg Oncol (2013) 1.52
Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol (2004) 1.52
Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol (2006) 1.52
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Peripherally administered CRF stimulates colonic motility via central CRF receptors and vagal pathways in conscious rats. Am J Physiol Regul Integr Comp Physiol (2005) 1.50
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.49
Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.49
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol (2003) 1.49
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park) (2010) 1.48
Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol (2006) 1.47
The impact of functional dependency on outcomes after complex general and vascular surgery. Ann Surg (2015) 1.45
Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44
Inguinal hernia: an old condition with new solutions. Ann Surg (2003) 1.44
Racial disparities in outcomes after appendectomy for acute appendicitis. Am J Surg (2011) 1.44
Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys (2004) 1.41
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
Electroacupuncture at ST-36 accelerates colonic motility and transit in freely moving conscious rats. Am J Physiol Gastrointest Liver Physiol (2005) 1.40